The Cell Cycle-Associated Protein CDKN2A May Promotes Colorectal Cancer Cell Metastasis by Inducing Epithelial-Mesenchymal Transition

Wei-Kun Shi†, Yun-Hao Li†, Xue-Shan Bai2 and Guo-Le Lin†*

† Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, 2 Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Colorectal cancer (CRC) is a common gastrointestinal malignancy, and recurrence and metastasis contribute considerably to its high mortality. It is well known that the epithelial-mesenchymal transition (EMT) accelerates the rate of cancer cell dissemination and migration, thus promoting cancer metastasis. Targeted therapy is a common modality for cancer treatment, and it can play a role in inhibiting cancer progression. In this study, bioinformatics was used to search for genes associated with the prognosis of CRC. First, differential analysis was performed on colon and rectal cancer samples to obtain 2,840 and 3,177 differentially expressed genes (DEGs), respectively. A Venn diagram was then used to identify 262 overlapping genes from the two groups of DEGs and EMT-related genes. The overlapping genes were subjected to batch survival analysis and batch expression analysis successively, and nine genes were obtained whose high expression in CRC led to a poor prognosis. The least absolute shrinkage and selection operator (LASSO) prognostic model was then constructed to obtain the risk score formula. A nomogram was constructed to seek prognostic independent factors to obtain CDKN2A. Finally, CCK-8 assay, flow cytometry and western blotting assays were performed to analyze the cellular biological function of CDKN2A. The results showed that knockdown of CDKN2A expression inhibited HT-29 cell proliferation, promoted apoptosis and cell cycle progression, and affected the EMT process in CRC.

Keywords: CDKN2A, colorectal cancer, epithelial-mesenchymal transition, cancer metastasis, cell proliferation and migration

INTRODUCTION

Colorectal cancer (CRC) is a common gastrointestinal malignancy and the leading cause of cancer deaths. The 2020 global cancer statistics show that there were nearly 1.9 million new cases of CRC (9.8% of cases) and more than 900,000 deaths (9.2% of cases) (1). The five-year survival rate for CRC is highly stage-dependent: early-stage survival rates exceed 90%, while advanced-stage rates reach only 10% (2). This is because early-stage CRC is usually not easily detectable and is not diagnosed until it has spread substantially. Patients with CRC often exhibit symptoms such as...
signaling pathways can promote EMT in cancer cells (17). In targets. Previous studies have shown that the activation of certain involved in EMT can be regulated by a variety of kinases, and the change of epithelial cells to a mesenchymal state (13). In a addition, EMT can be induced by proteins and selectively trigger differentiation, and migration (16). The activity of the TFs progression by directly inhibiting cell proliferation, and certain metabolic pathways involved can directly contribute to EMT (10). In this context, EMT promotes cancer cell dissemination and migration by enhancing cell mobility, which leads to cancer metastasis (11). The hallmark alterations observed in cells undergoing EMT are reduced E-cadherin expression and enhanced N-cadherin and vimentin expression, which usually occur prior to tumor invasion (12). These modifications are mediated by multiple transcription factors (TFs) that directly repress E-cadherin expression and promote the change of epithelial cells to a mesenchymal state (13). In a variety of cancers, including CRC, EMT confers metastatic and stem cell properties on cancer cells (14). There is also evidence that EMT is associated with drug resistance to multiple drugs (15). Therefore, it is important to develop EMT inhibitors for cancer therapy.

Targeted therapies play a unique role in inhibiting cancer progression by directly inhibiting cell proliferation, differentiation, and migration (16). The activity of the TFs involved in EMT can be regulated by a variety of kinases, and their signaling pathways can also serve as effective therapeutic targets. Previous studies have shown that the activation of certain signaling pathways can promote EMT in cancer cells (17). In addition, EMT can be induced by proteins and selectively trigger gene expression programs in cancer stem cells (18).

Therefore, in this study, we focused on identifying EMT-related genes that are potentially associated with CRC prognosis and conducted in vitro experiments to validate the biological functions of these potential genes.

**MATERIALS AND METHODS**

**Data Sources**

Gene expression matrices and RNA-seq data of colon and rectal cancers were obtained from the TCGA database, as well as mRNA expression data of the corresponding normal tissue samples. The data contained 455 colon cancer samples and 165 rectal cancer samples, and they corresponded to 41 and 10 normal tissue samples, respectively. EMT-related gene sets were downloaded from the Molecular Signatures Database (MsigDB, https://www.gsea-msigdb.org/gsea/msigdb/) and contained 1,263 genes.

**Differential Analysis**

The R package Limma was used to study the differential expression of mRNAs, and P < 0.05 and |log2FC| > 1 were defined as the screening threshold for differential expression. The intersection of differentially expressed genes (DEGs) and EMT-related genes was determined using a Venn diagram constructed to obtain overlapping genes associated with colon cancer, rectal cancer, and EMT.

**Construction of the LASSO Prognostic Model**

The prognostic feature model was constructed using the R package glmnet to investigate the relationship between genes and CRC prognosis. The least absolute shrinkage and selection operator (LASSO) regression algorithm was used to select features using 10-fold cross-validation. The LASSO prognostic model is a risk score formula that includes multiple genes. The included samples were divided into two groups: high risk and low risk. The log-rank test was used for the survival analysis and to compare the survival difference between the two groups, and timeROC analysis was used to compare the predictive accuracy and risk scores of the pivotal genes.

**Survival Analysis**

Gene expression levels in cancer versus para cancer cells were compared using the t-test, and the R package ggplot2 was used for picture plotting. The R package survival was used to analyze survival differences between high- and low-expression groups, and the results are presented as KM survival curves, with P values and hazard ratios (HR) with 95% confidence intervals (95% CI) obtained by log-rank test and univariate Cox proportional hazards regression. Univariate and multivariate Cox analyses were used to identify prognostic independent factors. The R package forest plot was used to draw forest plots, and the R package “rms” was used to create column line plots (nomograms). P value < 0.05 was considered statistically significant.

**Cell Culture**

Human HT-29 CRC cells (HTB-38™) were purchased from the American Type Culture Collection (ATCC). The HT-29 cell line was cultured in McCoy’s 5A medium containing 10% FBS in a humidified incubator with 5% CO₂ at 37°C.

**SiRNA Transfection**

siRNA specifically targeting CDKN2A were designed and synthesis by GenePharma Corporation (Shanghai, China), the sequence of sense is GGGUCCCAGUCGCAGUUATT, the sequence of antisense is UAAAGAGACUGGGACCCCTT. Cells were added to 6-well plates and cultured for 24 h. siRNA was transfected into cells using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. The medium was replaced after 6 h with fresh medium containing 10% FBS, and the cells were collected after 24 h for
the following assays. The negative control group consisted of si-
NC transfection-treated HT-29 cells, which were cultured in
parallel, as described above.

**Cell Proliferation Assay**
Cells were added to 96-well plates and incubated overnight for
cell transfection. They continued to be incubated at 37°C in a
humid atmosphere of 5% CO₂, CCK-8 reagent was added to the
wells 0, 6, 12, 24, 48, or 72 h post-transfection, and the cells were
incubated for 2 h. The absorbance values (optical density, OD)
were measured at 450 nm using an enzyme marker.

**Western Blotting**
Cells were lysed using RIPA buffer, and the total protein
concentration was determined using the BCA assay. Total proteins
were separated using 10% SDS-PAGE and transferred to
polyvinylidene difluoride membranes. The membranes were
blocked with 5% skim milk diluted in TBST for 1 h and then
incubated with primary antibodies overnight at 4°C. The primary
antibodies were anti-CDKN2A (ab185620, abcam), anti-N-
cadherin (ab245117, abcam), anti-E-cadherin (ab40772, abcam),
anti-vimentin (ab92547, abcam), and anti-β-actin (ab8226,
abcam). After washing, the secondary antibody coupled to
horseradish peroxide was added, and the membranes were
incubated for 2 h at room temperature. Protein bands were
detected using an enhanced chemiluminescence kit.

**Flow Cytometry Assay**
The effect of CDKN2A on the apoptosis and cell cycle processes
of HT-29 cells was analyzed using flow cytometry. For apoptosis,
the transfected cells were collected and treated with trypsin, and
the supernatant was removed after centrifugation at 3,000 × g at
room temperature. Cells were suspended in the binding buffer
according to the supplier’s instructions and stained with
membrane-linked protein V-FITC/Propidium iodide (PI) in
the dark, and then the apoptosis rate was determined using
flow cytometry. Similarly, transfected HT-29 cells were collected,
fixed overnight in 75% ethanol at 4°C, stained with PI according
to the manufacturer’s instructions, and subsequently subjected to
a cell cycle assay using flow cytometry.

**RESULTS**

**Differential Analysis**
Differential analysis was performed for colon cancer (T = 455,
Nor = 41) and rectal cancer (T = 165, Nor = 10), and the results
showed that there were 1,401 upregulated genes and 1,439
downregulated genes in colon cancer (Figure 1A), and 1,356
upregulated genes and 1,821 downregulated genes in rectal
cancer (Figure 1B). The intersection results showed that there
were 262 overlapping genes among the differential genes and
EMT-related genes (Figure 1C). Survival analysis was performed
on the 262 overlapping genes, of which 24 genes were associated
with prognosis (Figure 2A). The genes with a risk ratio (HR) > 1
were subsequently subjected to bulk expression analysis, and
nine genes were highly expressed in CRC tissues and six genes
were highly expressed in paracancer tissues (Figure 2B).

**Construction of the Prognostic Risk Model**
The nine EMT-related genes that were found to be highly expressed
in CRC cells were subjected to LASSO regression analysis to
construct characteristic prognostic models (Figures 3A, B). When
the minimum lambda value was 0.0114, the following risk score
formula was obtained: Riskscore = (0.1879)*PLOD3+(0.0427)
*STC2+(0.1019)*CDKN2A+(0.0578)*SNAI1+(0.3033)*TIMP1.
According to the calculation results of the formula, the samples are
divided into high-risk group and low-risk group (Figure 3C). The
KM survival curves demonstrated the difference in survival between
the high-risk and low-risk groups, with the low-risk group found to
have better survival compared to the high-risk group (Figure 3D).

**CDKN2A Is an Independent Prognostic Factor for Colorectal Cancer (CRC)**
Genes in the risk score formula were defined as risk genes, and a
nomogram was constructed to analyze the prognostic value of the
five risk genes. Combining the results of the univariate and
multifactorial Cox analyses showed CDKN2A to be an
independent prognostic factor for CRC, and that age and M
stage are also significant (Figures 4A, B). The nomogram model
gave good predictive power and demonstrated the prognostic
predictive ability of each factor for CRC (Figures 4C, D).

**Comparison of CDKN2A Expression With Survival**
To further understand the prognostic significance of CDKN2A in
CRC, we analyzed the prognosis in terms of the three survival types.
The results for overall survival (OS) (Figure 5A), progression-free
survival (PFS) (Figure 5B), and disease-specific survival (DSS)
(Figure 5C) showed that high CDKN2A expression indicated a
worse prognosis. The median OS time was 28.8 months longer for
patients with low CDKN2A expression compared to those with
high CDKN2A expression. The ROC curves of OS (Figure 5D),
PFS (Figure 5E) and DSS (Figure 5F) show the area under the
curve (AUC) for this risk score is around 0.6.

**Knockdown of CDKN2A Expression Inhibits HT-29 Cell Proliferation**
The cell proliferative ability was then determined via a CCK-8
assay. The results showed that knockdown of CDKN2A
expression inhibited cell proliferation (Figure 6A).

**CDKN2A Promotes CRC Progression Via Epithelial-Mesenchymal Transition (EMT)**
To verify the relationship between CDKN2A and EMT in CRC
cells, we determined the protein levels of EMT signaling
pathway-related molecules using WB. The results showed that
knockdown of CDKN2A expression in HT-29 cells led to
enhanced of E-cadherin expression and suppression expression
of N-cadherin and vimentin at the protein levels compared with
the negative control cells (Figure 6B). Thus, it is evident that
knockdown of CDKN2A expression inhibits EMT in CRC cells.
CDKN2A Is Involved in the Regulation of Cell Cycle and Apoptosis of HT-29 Cells

Flow cytometry was utilized to understand the effect of CDKN2A on the cell cycle and apoptosis. Compared with the negative control cell samples, the percentage of G1 phase cells in the treated HT-29 cell samples increased significantly (Figure 6C). Also, the percentage of apoptotic HT-29 cells was significantly higher in the cell samples with knocked-down CDKN2A than in the control cell samples (Figure 6D).

**DISCUSSION**

CRC is a highly lethal cancer, and its mortality is mainly attributed to recurrence and distant metastasis (19). There is a strong association between EMT and tumor metastasis, and EMT has been identified as a major cause of CRC metastasis (20). In this study, bioinformatics analysis showed that CDKN2A (p14) was an independent prognostic factor of colorectal cancer, and its high expression could induce EMT and mediate adverse clinical outcomes in CRC patients.

CDKN2A mainly encodes two proteins, p14 and p16 (21). p16 protein is a cyclin dependent kinase inhibitor, which can bind with CDK4 and CDK6 and prevent the phosphorylation of retinoblastoma protein, so as to prevent the process of cell cycle (22). p14 protein is a splice variant of CDKN2A. It has no amino acid homology with p16 due to frameshift, and can regulate the activity of p53 (23). As a tumor suppressor, CDKN2A is involved in B-cell differentiation, cell survival, and cell cycle progression (24). CDKN2A is also associated with cancer prognosis. Deletion of CDKN2A is associated with a poor prognosis in soft tissue sarcomas and is an independent prognostic factor in HPV-negative head and
FIGURE 2 | Batch survival and expression analysis. (A) Results of batch survival analysis of overlapping genes, HR > 1 indicates that the gene is a protective factor for cancer; and (B) expression analysis of genes with survival significance. **P < 0.01, ***P < 0.001.

FIGURE 3 | Establishment of the least absolute shrinkage and selection operator (LASSO)-Cox prognostic model. (A, B) Selected characteristic coefficients are shown by lambda parameters, and the number of prognostic factors was determined using LASSO regression analysis; (C) distribution of high and low risk samples; (D) KM survival analysis of the high- and low-risk samples for CRC in the TCGA dataset.
Identification of independent prognostic factors for CRC and single-gene prognostic analysis. (A) Single-factor Cox regression analysis; (B) multi-factor Cox regression analysis; and (C, D) the nomogram model used to predict the OS of patients with CRC at one, three, and five years. p < 0.05 was considered statistically significant.

Comparison of different survival types. (A-C) The OS, PFS and DSS of patients with CRC who expressed high levels of CDKN2A. (D-F) ROC curves of OS, PFS and DSS. p < 0.05 was considered statistically significant.
neck squamous cell carcinomas (21, 25). Some reports suggest that hypermethylated CDKN2A is a predictor of poor prognosis of colorectal cancer (26). Interestingly, we also found that high CDKN2A expression is an independent prognostic factor for CRC and is associated with a poor prognosis. The reason for the contradiction between the two conclusions may be related to the heterogeneity between samples. In addition, there are regional differences in the risk of poor prognosis of colon cancer caused by CDKN2A methylation. In addition, the mechanism by which CDKN2A promotes CRC progression has been investigated. It may promote the proliferation and metastasis of tumor cells through ILF3-AS1/EZH2/H3K27me3/CDKN2A axis (27). Different from that study, in this study we analyzed the relationship between CDKN2A and colorectal cancer metastasis from EMT.

EMT plays an important role in tumor metastasis. The onset of the EMT process was often accompanied by decreased expression of E-cadherin and enhanced expression of N-cadherin and vimentin. E-cadherin is a transmembrane protein, and its downregulation is usually associated with the invasion of early tumor cells. N-cadherin is commonly found in non-epithelial cells, and its upregulation induces EMT and cancer stem cell properties (28). Vimentin is an intermediate filament protein that regulates cellular traits and migratory capacity during cell metastasis to support the EMT phenomenon (29). It is reported that EMT related prognostic features can not only be used as a prediction tool for high recurrence risk of cancer (30), but also promote invasion and metastasis (31). In the present study, WB results showed that knocking down CDKN2A expression in HT-29 cells was followed by enhanced E-cadherin expression and suppression of N-cadherin and vimentin expression. This implies that CDKN2A can induce EMT. Coincidentally, the occurrence of cancer invasion and metastasis is often related to EMT. In pancreatic cancer and melanoma, CDKN2A is often noticed due to mutations (22, 32). It is also reported that CDKN2A is lost in locally advanced or metastatic tumor tissues (33). Studies have shown that the mutation or defect of CDKN2A in cancer cells can induce EMT, so as to promote the invasion and metastasis of cancer cells (34, 35). The inactivation of p14 protein can worsen colorectal cancer and lead to tumor size (36).

In conclusion, this study combined bioinformatics analysis with in vitro assays to identify CDKN2A as an independent...
prognostic factor in CRC and to confirm its biological role. The results show that CDKN2A (p14) has a protumor effect, and the increase of its expression can induce the occurrence of EMT.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found here: https://www.gsea-msigdb.org/gsea/msigdb/.

**REFERENCES**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660
2. Van der Jeugt K, Xu H-C, Li Y-J, Lu X-B, Ji G. Drug Resistance and New Therapies in Colorectal Cancer. World J Gastroenterol (2018) 24(34):3834. doi: 10.3748/wjg.v24.i34.3834
3. Mattuzzi C, Sanchis-Gomar F, Lippi G. Concise Update on Colorectal Cancer Epidemiology. Ann Trans Med (2017) 7(21):609. doi: 10.21037/atm.2019.07.91
4. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. doi: 10.3322/caac.21551
5. Hampel H, de la Chapelle A. The Search for Unaffected Individuals With Lynch Syndrome: Do the Ends Justify the Means? Cancer Prev Res (2011) 4(1):1–5. doi: 10.1158/1940-6207.CAPR-10-0345
6. Keun N, Giovannucci E. Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies. Nat Rev Gastroenterol Hepatol (2019) 16(12):713–32. doi: 10.1038/s41577-019-0189-8
7. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. doi: 10.3322/caac.21551
8. Pastushenko I, Blanpain C. EMT Transition States During Tumor Progression and Metastasis. Trends Cell Biol (2019) 29(5):212–26. doi: 10.1016/j.tcb.2018.12.001
9. Derynck R, Weinberg RA. EMT and Cancer: More Than Meets the Eye. Nat Rev Cancer (2013) 13(1):5–9. doi: 10.1038/nrc3411
10. Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, Zaravinos A. EMT Factors and Metabolic Pathways in Cancer. Front Oncol (2020) 10:499. doi: 10.3389/fonc.2020.00499
11. Aiello NM, Kang Y. Context-Dependent EMT Programs in Cancer Metastasis. J Exp Med (2019) 216(5):1016–26. doi: 10.1084/jem.20181827
12. Zeng Q, Zhang Y, Zhang W, Guo Q. Baicalein Suppresses the Proliferation of Epithelial–Mesenchymal Transition. Mol Med Rep (2020) 216(5):1016–26. doi: 10.3892/mmr.2020.11051
13. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in Cancer. Nat Rev Cancer (2008) 8(1):51–62. doi: 10.1038/nrc2252
14. Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive Review of Targeted Therapy Technology Projects under grant No. D171100002617003.
15. Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, et al. CDKN2A Deletion as a Biomarker for Poor Prognosis. Clin Sarcoma Res (2019) 9(1):1–11. doi: 10.1186/s13569-019-0122-5
16. Zeng H, Jorapur A, Shain AH, Lang UE, Torres R, Zhang Y, et al. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. Cancer Cell (2018) 34(1):56–68. doi: 10.1016/j.ccell.2018.05.014
17. Inoue K, Fry EA. Aberrant Expression of P14arf in Human Cancers: A New Biomarker? Tumor Microenvironment (2018) 1(2):37. doi: 10.4103/tme.tme_24_17
18. Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Öbländer J, et al. Genomic CDKN2A/2B Deletions in Adult Ph+ ALL are Adverse Despite Allogeneic Stem Cell Transplantation. Blood (2018) 131(13):1464–75. doi: 10.1182/blood-2017-07-796862
19. Chen WS, Bindra RS, Mo A, Hayman T, Husain Z, Contessa JN, et al. CDKN2A Copy Number Loss is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Front Oncol (2018) 8:95. doi: 10.3389/fonc.2018.00095
20. Bui NQ, Przybyl J, Trubucco SE, Frampton G, Hastie T, van de Rijn M, et al. A Clinico-Genomic Analysis of Soft Tissue Sarcoma Patients Reveals CDKN2A Deletion as a Biomarker for Poor Prognosis. J Clin Pathol (2019) 70(3):209. doi: 10.1136/jclinpath-2018-202499
21. Wang X, Lai Q, He C, Fang Y, Yan Q, Zhang Y, et al. RUNX1 Promotes Tumour Metastasis by Activating the Wnt/β-Catenin Signalling Pathway and EMT in Colorectal Cancer. J Exp Clin Cancer Res (2019) 38(1):1–13. doi: 10.1186/s13046-019-1330-9
22. Li T, Hu P-S, Zuo Z, Lin J-F, Li W, Xu Q-N, et al. METTL3 Facilitates Tumor Progression via an M6A-IGF2BP2-Dependent Mechanism in Colorectal Carcinoma. Mol Cancer (2019) 18(1):1–15. doi: 10.1186/s12943-019-1038-7
23. Lin J, Shi Z, Yu Z, He Z. LncRNA HIF1A-AS2 Positively Affects the Progression and EMT Formation of Colorectal Cancer Through Regulating miR-129-5p and DNMT3A. Biomed Pharmacother (2018) 96:433–9. doi: 10.1016/j.biopha.2017.12.058
24. Wang K, Song K, Ma Z, Yao Y, Liu C, Yang J, et al. Identiﬁcation of a Candidate Prognostic Biomarker for High-Risk Stage II Colorectal Cancer and Characterisation of Metastasis-Related Genes. Br J Cancer (2020) 123(3):410–17. doi: 10.1038/s41416-020-0902-y
25. Wang X, Lai Q, He J, Li Q, Ding J, Lan Z, et al. LncRNA SNHG6 Promotes Proliferation, Invasion and Migration in Colorectal Cancer Cells by Activating TGF-β/Smad Signaling Pathway via Targeting UPF1 and Inducing EMT via Regulation of ZEB1. Int J Med Sci (2019) 16(1):51. doi: 10.7150/ijms.27359
26. Tu Q, Hao J, Zhou X, Yan L, Dai H, Sun B, et al. CDKN2B Deletion is Essential for Pancreatic Cancer Development Instead of Unmeaningful Co-Deletion Due to Juxtaposition to CDKN2A. Oncogene (2018) 37(1):128–38. doi: 10.1038/onc.2017.316

**AUTHOR CONTRIBUTIONS**

WS and YL contributed equally to this work. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by Beijing Major Science and Technology Projects under grant No. D171100002617003.
33. Yang C, Cimera RS, Aryequaye R, Jayakumaran G, Sarungham J, Al-Ahmadi HA, et al. Adverse Histology, Homozygous Loss of CDKN2A/B, and Complex Genomic Alterations in Locally Advanced/Metastatic Renal Mucinous Tubular and Spindle Cell Carcinoma. *Mod Pathol* (2021) 34 (2):445–56. doi: 10.1038/s41379-020-00667-9
34. Merkle J, Breunig M, Schmid M, Allgöwer C, Krüger J, Melzer MK, et al. CDKN2A-Mutated Pancreatic Ductal Organoids From Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome. *Cancers* (2021) 13 (20):5139. doi: 10.3390/cancers13205139
35. Jeong E-H, Lee T-G, Ko YJ, Kim SY, Kim H-R, Kim H, et al. Anti-Tumor Effect of CDK Inhibitors on CDKN2A-Defective Squamous Cell Lung Cancer Cells. *Cell Oncol* (2018) 41(6):663–75. doi: 10.1007/s13402-018-0404-6
36. Hibi K, Nakayama H, Koike M, Kasai Y, Ito K, Akiyama S, et al. Colorectal Cancers With Both P16 and P14 Methylation Show Invasive Characteristics. *Jpn J Cancer Res* (2002) 93(8):883–7. doi: 10.1111/j.1349-7006.2002.tb01333.x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Shi, Li, Bai and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*